BB BIOTECH AG

  • WKN: A0NFN3
  • ISIN: CH0038389992
  • Land: Switzerland

Nachricht vom 26.04.2019 | 06:30

BB Biotech AG reports results

BB BIOTECH AG / Key word(s): Interim Report
BB Biotech AG reports results

26-Apr-2019 / 06:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Media Release, April 26, 2019
 

BB Biotech AG reports results


In accordance with regulations on ad hoc publicity, BB Biotech AG is releasing the following information about its results of the interim financial statements as of March 31, 2019.

Based on consolidated results, BB Biotech AG reports for the first quarter a profit of CHF 890 mn (profit of CHF 28 mn in the corresponding period of the previous year) was incurred. As an investment company, the result reflects the performance of the stocks it holds in its investment portfolio.

Since beginning of the year, BB Biotech AG's share price increased 24.2% in CHF and 25.4% in EUR.

The interim report as of March 31, 2019 will be published on April 26, 2019 at 7 am.


For further information:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Tanja Chicherio, Tel. +41 44 267 67 07, tch@bellevue.ch

www.bbbiotech.com

 

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.


26-Apr-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Fonds Research 2019: Dt. Mittelstandsanleihen FONDS bietet attraktive Anlagemöglichkeit

Auch 2019 hat die GBC AG unter der Vielzahl an Publikumsfonds neun „Fonds Champions“ herausgefiltert. Darunter den Deutsche Mittelstandsanleihen FONDS (ISIN: LU0974225590), der eine qualitätsorientierte Strategie verfolgt und eine vielversprechende Anlagemöglichkeit in den deutschen Mittelstand bietet. Insbesondere vor dem Hintergrund des aktuellen Niedrigzinsniveaus sehen wir den Fonds als gute Chance, um attraktive Renditen zu erwirtschaften und dies verbunden mit einer traditionell niedrigen Fonds-Volatilität. Wir vergeben 5 von 5 GBC-Falken ein.

Aktuelle Research-Studie

Original-Research: dynaCERT Inc (von GBC AG): BUY dynaCERT Inc

20. September 2019